Efficacy and safety of tolterodine extended-release in men with overactive bladder symptoms treated with an α-blocker: Effect of baseline prostate-specific antigen concentration

BJU International

Volumn 106, Issue 9, 2010, Pages 1332-1338

  Chapple, Christopher R ^a   Herschorn, Sender ^c   Abrams, Paul ^b   Wang, Joseph T ^d   Brodsky, Marina ^d   Guan, Zhonghong ^d  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^b SOUTHMEAD HOSPITAL   (United Kingdom)

^c UNIVERSITY OF TORONTO   (Canada)

^d PFIZER INC   (United States)

Author keywords

antimuscarinic; efficacy; overactive bladder; prostate specific antigen; safety; tolterodine ER

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; PLACEBO; PROSTATE SPECIFIC ANTIGEN; TOLTERODINE;

ADULT; AGE; AGED; ARTICLE; BLADDER CATHETERIZATION; BLURRED VISION; CIRCADIAN RHYTHM; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSURIA; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICTURITION; MONOTHERAPY; OVERACTIVE BLADDER; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RESIDUAL URINE; SOMNOLENCE; TREATMENT DURATION; URINARY HESITANCY; URINARY URGENCY; URINE FLOW RATE; URINE INCONTINENCE; URINE RETENTION; XEROSTOMIA;

ADRENERGIC ALPHA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; BENZHYDRYL COMPOUNDS; CRESOLS; DELAYED-ACTION PREPARATIONS; DRUG THERAPY, COMBINATION; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PHENYLPROPANOLAMINE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE;

EID: 78349250963     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09359.x     Document Type: Article

References (38)

1. Chapple CR, Roehrborn CG,. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 2006; 49: 651-8
2. Abrams P, Artibani W, Cardozo L, Dmochowski R, Van Kerrebroeck P, Sand P., Reviewing the ICS 2002 Terminology Report: the ongoing debate. Neurourol Urodyn 2006; 25: 293
3. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006; 50: 1306-15
4. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20: 327-36
5. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ,. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87: 760-6
6. Hyman MJ, Groutz A, Blaivas JG,. Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. J Urol 2001; 166: 550-3
7. Oelke M, Baard J, Wijkstra H, De La Rosette JJ, Jonas U, Hofner K., Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia. Eur Urol 2008; 54: 419-26
8. De Nunzio C, Franco G, Rocchegiani A, Iori F, Leonardo C, Laurenti C., The evolution of detrusor overactivity after watchful waiting, medical therapy and surgery in patients with bladder outlet obstruction. J Urol 2003; 169: 535-9
9. Machino R, Kakizaki H, Ameda K, et al. Detrusor instability with equivocal obstruction: a predictor of unfavorable symptomatic outcomes after transurethral prostatectomy. Neurourol Urodyn 2002; 21: 444-9
10. Sussman DO., Overactive bladder: treatment options in primary care medicine. J Am Osteopath Assoc 2007; 107: 379-85
11. Chapple C, Herschorn S, Abrams P, Sun F, Brodsky M, Guan Z,. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol 2009; 56: 534-41
12. Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fisfis J, Perimenis P, Barbalias G,. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol 2003; 169: 2253-6
13. Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z,. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006; 296: 2319-28
14. Lee JY, Kim HW, Lee SJ, Koh JS, Suh HJ, Chancellor MB,. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 2004; 94: 817-20
15. Abrams P, Kaplan SA, De Koning Gans HJ, Millard R., Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 2006; 175: 999-1004
16. Kaplan SA, Walmsley K, Te AE,. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 2005; 174: 2273-6
17. Kaplan SA, Roehrborn CG, Dmochowski R, Rovner ES, Wang JT, Guan Z,. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. Urology 2006; 68: 328-32
18. Hofner K, Burkart M, Jacob G, Jonas U,. Safety and efficacy of tolterodine extended release in men with overactive bladder symptoms and presumed non-obstructive benign prostatic hyperplasia. World J Urol 2007; 25: 627-33
19. Roehrborn CG, Abrams P, Rovner ES, Kaplan SA, Herschorn S, Guan Z,. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU Int 2006; 97: 1003-6
20. MacDiarmid SA, Peters KM, Chen A, et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clin Proc 2008; 83: 1002-10
21. Staskin DR, Rosenberg MT, Dahl NV, Polishuk PV, Zinner NR,. Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions. Int J Clin Pract 2008; 62: 27-38
22. Lee KS, Choo MS, Kim DY, et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J Urol 2005; 174: 1334-8
23. Ronchi P, Gravina GL, Galatioto GP, Costa AM, Martella O, Vicentini C,. Urodynamic parameters after solifenacin treatment in men with overactive bladder symptoms and detrusor underactivity. Neurourol Urodyn 2009; 28: 52-7
24. Herschorn S, Jones JS, Oelke M, MacDiarmid S, Wang JT, Guan Z., Efficacy and tolerability of fesoterodine in men with overactive bladder: a pooled analysis of 2 phase III studies. Urology 2009 [Epub ahead of print]. DOI: 10.1016/j.urology.200909.007
25. Yokoyama T, Uematsu K, Watanabe T, Sasaki K, Kumon H, Nagai A,. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study. Scand J Urol Nephrol 2009; 43: 307-14
26. Roehrborn CG, Kaplan SA, Kraus SR, Wang JT, Bavendam T, Guan Z,. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB. Urology 2008; 72: 1061-7
27. Roehrborn CG, Boyle P, Gould AL, Waldstreicher J,. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 1999; 53: 581-9
28. Roehrborn CG, McConnell J, Bonilla J, et al. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. J Urol 2000; 163: 13-20
29. Roehrborn CG, McConnell JD, Lieber M, et al. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group. Urology 1999; 53: 473-80
30. Roehrborn CG, Malice M, Cook TJ, Girman CJ,. Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH. a comprehensive analysis of the pooled placebo groups of several large clinical trials. Urology 2001; 58: 210-6
31. Roehrborn CG, McConnell JD, Saltzman B, et al. Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes. Eur Urol 2002; 42: 1-6
32. Crawford ED, Wilson SS, McConnell JD, et al. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol 2006; 175: 1422-7
33. Coyne KS, Tubaro A, Brubaker L, Bavendam T,. Development and validation of patient-reported outcomes measures for overactive bladder: a review of concepts. Urology 2006; 68 (Suppl.): 9-16
34. Yang Y, Zhao XF, Li HZ, et al. Efficacy and safety of combined therapy with terazosin and tolterodine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study. Chin Med J (Engl) 2007; 120: 370-4
35. Martín-Merino E, García-Rodríguez LA, Masso-Gonzalez EJ, Roehrborn CG., Do oral antimuscarinic drugs carry an increased risk of acute urinary retention? J Urol 2009; 182: 1442-8
36. Abrams P, Andersson KE,. Muscarinic receptor antagonists for overactive bladder. BJU Int 2007; 100: 987-1006
37. Kaplan SA, Wein AJ, Staskin DR, Roehrborn CG, Steers WD,. Urinary retention and post-void residual urine in men: separating truth from tradition. J Urol 2008; 180: 47-54
38. Roehrborn CG, Kaplan SA, Jones JS, Wang JT, Bavendam T, Guan Z,. Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. Eur Urol 2009; 55: 472-81